|Support type:||Scholarships in Brazil - Scientific Initiation|
|Effective date (Start):||March 01, 2019|
|Effective date (End):||February 29, 2020|
|Field of knowledge:||Health Sciences - Medicine - Medical Clinics|
|Principal Investigator:||Sara Teresinha Olalla Saad|
|Grantee:||João Vitor de Paula Souza Luz|
|Home Institution:||Centro de Hematologia e Hemoterapia (HEMOCENTRO). Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil|
Acute Myeloid Leukemia (AML) is a systemic neoplasm that originates in the bone marrow and is responsible for 90% of all cases of acute leukemia in adults, being more common in people over 65 years of age, which have a worse prognosis. Chemotherapy is used for the treatment of AML and greater than 5 years of survival is achieved in about 20% of cases, however, there are elderly patients who do not tolerate aggressive therapy due to the high toxicity of chemotherapeutic agents. The bone marrow transplantation increases the survival rate for up to 50%, but patients with advanced age are usually ineligible for such treatment. Many chemotherapeutics used in the treatment of neoplasms, including AML, are derived from plants. Gallic acid (GA) is a natural product that can bring benefits to the treatment, with preventive properties and with low cost of production. It is described that AG is an antioxidant with epigenetic modulation properties, induction of cell death by apoptosis, antiproliferative activity and inhibition of angiogenesis against tumor cells. In addition, the AG still has low cytotoxicity, making it more interesting for the treatment of neoplasia, although studies on their effects in vivo on AML models have not been done yet. The objective of this study is to analyze the in vitro and in vivo effects of AG in AML models, and for this purpose, animals with xenograft implants of leukemic lines will be used.